Abstract: Liver cancer is a common and deadly malignant tumor worldwide, and the abnormalities of oncogenes play a pivotal role in its initiation and progression. In-depth exploration of the oncogene-mediated metabolic mechanisms in liver cancer is expected to open up new avenues for the precision treatment, thereby promoting the diagnosis and treatment improvement of the disease. This article introduces the abnormal conditions of oncogenes in liver cancer and clarifies how these abnormalities drive the reprogramming of liver cancer metabolic pathways through transcriptional regulation, post-translational modification, and other mechanisms, thereby supporting the proliferation and survival needs of tumor cells. Furthermore, the feasibility of combining existed liver cancer treatment with drugs targeting oncogeneinduced metabolic remodeling in liver cancer is discussed, aiming to provide ideas and references for optimizing the combined treatment plan of liver cancer, overcoming tumor drug resistance, improving the prognosis, and prolonging survival.